Rani Therapeutics

Rani Therapeutics Employees

12 people indexed:

Arvinder Dhalla

Vice President, Clinical Development

1g0qbq3f.b836zq@60919w9qwy4b1q6q.wkb Sign up to see email

3y48g4kq.1w85f8@14qqj4f0ffwj5yqz.yw4 Sign up to see email
Bella Vazquez

Vice President, Human Resources

4d7yk.00yggyg@98w63gjwwy5j79x9.7kj Sign up to see email

23161.335420y@wf8f539j4g0gk4ww.23j Sign up to see email
Betsy Gutierrez

Vice President, Quality Assurance

0wwd3.4kj13d976@889vj285dk53w4kx.7kw Sign up to see email

fwfd5.4011w1qwd@fl9wfjf526716x14.2lf Sign up to see email
Christopher Prue

Senior Director, Regulatory Affairs

kq61335qj27.32vv@q32lw3xj257ww3kx.lj2 Sign up to see email

b5xf046yv21.fz9z@2132b1jbdvjgd54f.19z Sign up to see email
Eric Groen

General Counsel

9qq2.xkb29@7d3lfb1wvkvy2128.2ww Sign up to see email

j52q.ywxdy@4jq42ldxw034170l.k4z Sign up to see email
Jacques Van Dam

Vice President, Medical Affairs

6723ky4.315.g7w@89b3l65zw9fkw1f8.y64 Sign up to see email

9xk7gkk.fk8.2bg@35wb81lkg1f73b0y.w56 Sign up to see email
Kate McKinley

Chief Business Officer

f137.54vbdj0q@q3w48v2227787dx6.gqb Sign up to see email

4v3g.bw7235bz@fd2714g17fv03447.zb9 Sign up to see email
Mir Hashim

Chief Scientific Officer

kjx.3jb24l@gwxf23g21b99yf7b.dkf Sign up to see email

fwz.6jw80g@58b3gb91xl80kgf5.g61 Sign up to see email
Mir Imran

Executive Chairman

78z.bkwx7@f4jy55zb8ql3xzjj.88l Sign up to see email

4wz.36k7x@013x8ff4k6q9qb38.6x4 Sign up to see email
Nash Nishtala

Associate VP of R&D

dd3q.7x8402q8@xdfk3byz46zb6572.69v Sign up to see email

6813.5v0q18k9@q2wqfx5502q3y7dz.3zv Sign up to see email
Svai Sanford

Chief Financial Officer

6l5w.wxqkj77@lz0w670yq5b0z513.2x1 Sign up to see email

531x.y4lw27x@jlwg2zg8gkxx17yj.704 Sign up to see email
Talat Imran

Chief Executive Officer

39wj9.gqjxg@107q4wyd2vb3z9b5.39b Sign up to see email

q91y2.85098@1yzyxb1jg01j50y2.y45 Sign up to see email

Rani Therapeutics Company Information

Rani Therapeutics, headquartered at 2051 Ringwood Ave, San Jose, CA 95131, has developed a disruptive technology for the oral delivery of biologics. Their RaniPill platform is capable of delivering a wide range of payloads, including proteins, peptides, and antibodies, with bioavailability comparable to or better than subcutaneous injections. This technology aims to replace painful injections, enhancing compliance and quality of life for patients with chronic conditions. The company has demonstrated high reliability, safety, and tolerability in humans through multiple preclinical and clinical studies. Their pipeline includes treatments for conditions such as osteoporosis, psoriatic arthritis, and diabetes. Notably, RT-111, an oral Ustekinumab Biosimilar, has shown positive Phase 1 results. The RaniPill capsule is designed to navigate through the stomach and inject the drug into the intestinal wall, ensuring minimal discomfort and high bioavailability. Rani Therapeutics holds a strong patent position covering both the platform and the drugs in combination with the platform.

Report inaccurate information